Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.

Item
http://www.wikidata.org/entity/Q35237134
Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102.A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09Safety and tolerability of Peg-grafeel™, a pegfilgrastim, for the prophylactic treatment of chemotherapy-induced neutropenia and febrile neutropenia: A prospective, observational, postmarketing surveillance study in India.Towards the next generation of biomedicines by site-selective conjugation.Neutrophils in cancer.Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research GrouEfficacy of reduced dose of pegfilgrastim in Japanese breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide therapy.Interstitial pneumonia following administration of pegfilgrastim during carboplatin and etoposide chemotherapy for small-cell lung cancer.Model-based optimization of G-CSF treatment during cytotoxic chemotherapy.Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.Prospective cohort study of febrile neutropenia in breast cancer patients with neoadjuvant and adjuvant chemotherapy: CSPOR-BC FN study."Same-Day" administration of pegfilgrastim following myelosuppressive chemotherapy: clinical practice and provider rationale.Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer.
P2860

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.

Item
http://www.wikidata.org/entity/Q35237134
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Phase III placebo-controlled, ...... cyclophosphamide chemotherapy.
@ast
Phase III placebo-controlled, ...... cyclophosphamide chemotherapy.
@en
type
label
Phase III placebo-controlled, ...... cyclophosphamide chemotherapy.
@ast
Phase III placebo-controlled, ...... cyclophosphamide chemotherapy.
@en
prefLabel
Phase III placebo-controlled, ...... cyclophosphamide chemotherapy.
@ast
Phase III placebo-controlled, ...... cyclophosphamide chemotherapy.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P5875
P698
P921
P932
P356
P1433
P1476
Phase III placebo-controlled, ...... cyclophosphamide chemotherapy.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P5875
P698
P921
P932